O	0	6	Effect
O	7	9	of
O	10	18	Adjuvant
B-intervention	19	29	Paclitaxel
I-intervention	30	33	and
I-intervention	34	45	Carboplatin
O	46	48	on
O	49	57	Survival
O	58	60	in
O	61	66	Women
O	67	71	With
O	72	78	Triple
O	78	79	-
O	79	87	Negative
O	88	94	Breast
O	95	101	Cancer
O	101	102	:
O	103	104	A
O	105	110	Phase
O	111	112	3
O	113	123	Randomized
O	124	132	Clinical
O	133	138	Trial
O	138	139	.

O	140	143	The
O	144	149	value
O	150	152	of
O	153	161	platinum
O	161	162	-
O	162	167	based
O	168	176	adjuvant
O	177	189	chemotherapy
O	190	192	in
O	193	201	patients
O	202	206	with
O	207	213	triple
O	213	214	-
O	214	222	negative
O	223	229	breast
O	230	236	cancer
O	237	238	(
O	238	242	TNBC
O	242	243	)
O	244	251	remains
O	252	265	controversial
O	265	266	,
O	267	269	as
O	270	274	does
O	275	282	whether
O	283	288	BRCA1
O	289	292	and
O	293	298	BRCA2
O	299	300	(
O	300	305	BRCA1
O	305	306	/
O	306	307	2
O	307	308	)
O	309	317	germline
O	318	326	variants
O	327	330	are
O	331	341	associated
O	342	346	with
O	347	355	platinum
O	356	365	treatment
O	366	377	sensitivity
O	377	378	.

O	379	381	To
O	382	389	compare
O	390	391	6
O	392	398	cycles
O	399	401	of
O	402	412	paclitaxel
O	413	417	plus
O	418	429	carboplatin
O	430	431	(
O	431	434	PCb
O	434	435	)
O	436	440	with
O	441	442	a
B-control	443	451	standard
I-control	451	452	-
I-control	452	456	dose
O	457	464	regimen
O	465	467	of
O	468	469	3
O	470	476	cycles
O	477	479	of
O	480	496	cyclophosphamide
O	496	497	,
O	498	508	epirubicin
O	508	509	,
O	510	513	and
O	514	526	fluorouracil
O	527	535	followed
O	536	538	by
O	539	540	3
O	541	547	cycles
O	548	550	of
O	551	560	docetaxel
O	561	562	(
O	562	565	CEF
O	565	566	-
O	566	567	T
O	567	568	)
O	568	569	.

O	570	574	This
O	575	580	phase
O	581	582	3
O	583	593	randomized
O	594	602	clinical
O	603	608	trial
O	609	612	was
O	613	622	conducted
O	623	625	at
O	626	627	9
O	628	634	cancer
O	635	642	centers
O	643	646	and
O	647	656	hospitals
O	657	659	in
B-location	660	665	China
O	665	666	.

O	667	674	Between
O	675	679	July
O	680	681	1
O	681	682	,
O	683	687	2011
O	687	688	,
O	689	692	and
O	693	698	April
O	699	701	30
O	701	702	,
O	703	707	2016
O	707	708	,
O	709	714	women
O	715	719	aged
B-age	720	722	18
I-age	723	725	to
I-age	726	728	70
I-age	729	734	years
B-eligibility	735	739	with
I-eligibility	740	748	operable
I-eligibility	749	753	TNBC
I-eligibility	754	759	after
I-eligibility	760	770	definitive
I-eligibility	771	778	surgery
I-eligibility	779	780	(
I-eligibility	780	786	having
I-eligibility	787	801	pathologically
I-eligibility	802	811	confirmed
I-eligibility	812	820	regional
I-eligibility	821	825	node
I-eligibility	825	826	-
I-eligibility	826	834	positive
I-eligibility	835	842	disease
I-eligibility	843	845	or
I-eligibility	846	850	node
I-eligibility	850	851	-
I-eligibility	851	859	negative
I-eligibility	860	867	disease
I-eligibility	868	872	with
I-eligibility	873	878	tumor
I-eligibility	879	887	diameter
I-eligibility	888	889	>
I-eligibility	889	891	10
I-eligibility	892	894	mm
I-eligibility	894	895	)
O	896	900	were
O	901	909	screened
O	910	913	and
O	914	922	enrolled
O	922	923	.

O	924	933	Exclusion
O	934	942	criteria
O	943	951	included
O	952	958	having
O	959	969	metastatic
O	970	972	or
O	973	980	locally
O	981	989	advanced
O	990	997	disease
O	997	998	,
O	999	1005	having
O	1006	1009	non
O	1009	1010	-
O	1010	1014	TNBC
O	1014	1015	,
O	1016	1018	or
O	1019	1028	receiving
O	1029	1041	preoperative
O	1042	1052	anticancer
O	1053	1060	therapy
O	1060	1061	.

O	1062	1066	Data
O	1067	1071	were
O	1072	1080	analyzed
O	1081	1085	from
O	1086	1094	December
O	1095	1096	1
O	1096	1097	,
O	1098	1102	2019
O	1102	1103	,
O	1104	1106	to
O	1107	1114	January
O	1115	1117	31
O	1117	1118	,
O	1119	1123	2020
O	1123	1124	,
O	1125	1129	from
O	1130	1133	the
O	1134	1140	intent
O	1140	1141	-
O	1141	1143	to
O	1143	1144	-
O	1144	1149	treat
O	1150	1160	population
O	1161	1163	as
O	1164	1176	prespecified
O	1177	1179	in
O	1180	1183	the
O	1184	1192	protocol
O	1192	1193	.

O	1194	1206	Participants
O	1207	1211	were
O	1212	1222	randomized
O	1223	1225	to
O	1226	1233	receive
O	1234	1237	PCb
O	1238	1239	(
O	1239	1249	paclitaxel
O	1250	1252	80
O	1253	1255	mg
O	1255	1256	/
O	1256	1258	m2
O	1259	1262	and
O	1263	1274	carboplatin
O	1275	1276	[
O	1276	1280	area
O	1281	1286	under
O	1287	1290	the
O	1291	1296	curve
O	1297	1298	=
O	1299	1300	2
O	1300	1301	]
O	1302	1304	on
O	1305	1309	days
O	1310	1311	1
O	1311	1312	,
O	1313	1314	8
O	1314	1315	,
O	1316	1319	and
O	1320	1322	15
O	1323	1328	every
O	1329	1331	28
O	1332	1336	days
O	1337	1340	for
O	1341	1342	6
O	1343	1349	cycles
O	1349	1350	)
O	1351	1353	or
O	1354	1357	CEF
O	1357	1358	-
O	1358	1359	T
O	1360	1361	(
O	1361	1377	cyclophosphamide
O	1378	1381	500
O	1382	1384	mg
O	1384	1385	/
O	1385	1387	m2
O	1387	1388	,
O	1389	1399	epirubicin
O	1400	1403	100
O	1404	1406	mg
O	1406	1407	/
O	1407	1409	m2
O	1409	1410	,
O	1411	1414	and
O	1415	1427	fluorouracil
O	1428	1431	500
O	1432	1434	mg
O	1434	1435	/
O	1435	1437	m2
O	1438	1443	every
O	1444	1445	3
O	1446	1451	weeks
O	1452	1455	for
O	1456	1457	3
O	1458	1464	cycles
O	1465	1473	followed
O	1474	1476	by
O	1477	1486	docetaxel
O	1487	1490	100
O	1491	1493	mg
O	1493	1494	/
O	1494	1496	m2
O	1497	1502	every
O	1503	1504	3
O	1505	1510	weeks
O	1511	1514	for
O	1515	1516	3
O	1517	1523	cycles
O	1523	1524	)
O	1524	1525	.

O	1526	1529	The
O	1530	1537	primary
O	1538	1541	end
O	1542	1547	point
O	1548	1551	was
B-outcome-Measure	1552	1559	disease
I-outcome-Measure	1559	1560	-
I-outcome-Measure	1560	1564	free
I-outcome-Measure	1565	1573	survival
I-outcome-Measure	1574	1575	(
I-outcome-Measure	1575	1578	DFS
I-outcome-Measure	1578	1579	)
O	1579	1580	.

O	1581	1590	Secondary
O	1591	1594	end
O	1595	1601	points
O	1602	1610	included
B-outcome-Measure	1611	1618	overall
I-outcome-Measure	1619	1627	survival
I-outcome-Measure	1627	1628	,
I-outcome-Measure	1629	1636	distant
I-outcome-Measure	1637	1640	DFS
O	1640	1641	,
B-outcome-Measure	1642	1649	relapse
I-outcome-Measure	1649	1650	-
I-outcome-Measure	1650	1654	free
I-outcome-Measure	1655	1663	survival
O	1663	1664	,
B-outcome-Measure	1665	1668	DFS
I-outcome-Measure	1669	1671	in
I-outcome-Measure	1672	1680	patients
I-outcome-Measure	1681	1685	with
I-outcome-Measure	1686	1694	germline
I-outcome-Measure	1695	1703	variants
I-outcome-Measure	1704	1706	in
I-outcome-Measure	1707	1712	BRCA1
I-outcome-Measure	1712	1713	/
I-outcome-Measure	1713	1714	2
I-outcome-Measure	1715	1717	or
I-outcome-Measure	1718	1728	homologous
I-outcome-Measure	1729	1742	recombination
I-outcome-Measure	1743	1749	repair
I-outcome-Measure	1750	1751	(
I-outcome-Measure	1751	1754	HRR
I-outcome-Measure	1754	1755	)
I-outcome-Measure	1755	1756	-
I-outcome-Measure	1756	1763	related
I-outcome-Measure	1764	1769	genes
I-outcome-Measure	1769	1770	,
O	1771	1774	and
B-outcome-Measure	1775	1783	toxicity
O	1783	1784	.

O	1785	1786	A
O	1787	1792	total
O	1793	1795	of
B-total-participants	1796	1799	647
O	1800	1808	patients
O	1809	1810	(
O	1810	1814	mean
O	1815	1816	[
O	1816	1818	SD
O	1818	1819	]
O	1820	1823	age
O	1823	1824	,
B-age	1825	1827	51
I-age	1828	1829	[
I-age	1829	1831	44
I-age	1831	1832	-
I-age	1832	1834	57
I-age	1834	1835	]
I-age	1836	1841	years
O	1841	1842	)
O	1843	1847	with
O	1848	1856	operable
O	1857	1861	TNBC
O	1862	1866	were
O	1867	1877	randomized
O	1878	1880	to
O	1881	1888	receive
O	1889	1892	CEF
O	1892	1893	-
O	1893	1894	T
O	1895	1896	(
O	1896	1897	n
O	1898	1899	=
B-control-participants	1900	1903	322
O	1903	1904	)
O	1905	1907	or
O	1908	1911	PCb
O	1912	1913	(
O	1913	1914	n
O	1915	1916	=
B-intervention-participants	1917	1920	325
O	1920	1921	)
O	1921	1922	.

O	1923	1925	At
O	1926	1927	a
O	1928	1934	median
O	1935	1941	follow
O	1941	1942	-
O	1942	1944	up
O	1945	1947	of
O	1948	1950	62
O	1951	1957	months
O	1957	1958	,
B-outcome	1959	1962	DFS
I-outcome	1963	1967	time
O	1968	1971	was
O	1972	1978	longer
O	1979	1981	in
O	1982	1987	those
O	1988	1996	assigned
O	1997	1999	to
O	2000	2003	PCb
O	2004	2012	compared
O	2013	2017	with
O	2018	2021	CEF
O	2021	2022	-
O	2022	2023	T
O	2024	2025	(
B-outcome	2025	2026	5
I-outcome	2026	2027	-
I-outcome	2027	2031	year
I-outcome	2032	2035	DFS
O	2035	2036	,
B-iv-bin-percent	2037	2039	86
I-iv-bin-percent	2039	2040	.
I-iv-bin-percent	2040	2041	5
I-iv-bin-percent	2041	2042	%
O	2043	2045	vs
B-cv-bin-percent	2046	2048	80
I-cv-bin-percent	2048	2049	.
I-cv-bin-percent	2049	2050	3
I-cv-bin-percent	2050	2051	%
O	2051	2052	,
O	2053	2059	hazard
O	2060	2065	ratio
O	2066	2067	[
O	2067	2069	HR
O	2069	2070	]
O	2071	2072	=
O	2073	2074	0
O	2074	2075	.
O	2075	2077	65
O	2077	2078	;
O	2079	2081	95
O	2081	2082	%
O	2083	2085	CI
O	2085	2086	,
O	2087	2088	0
O	2088	2089	.
O	2089	2091	44
O	2091	2092	-
O	2092	2093	0
O	2093	2094	.
O	2094	2096	96
O	2096	2097	;
O	2098	2099	P
O	2100	2101	=
O	2102	2103	.
O	2103	2105	03
O	2105	2106	)
O	2106	2107	.

O	2108	2115	Similar
O	2116	2124	outcomes
O	2125	2129	were
O	2130	2138	observed
O	2139	2142	for
B-outcome	2143	2150	distant
I-outcome	2151	2154	DFS
I-outcome	2155	2158	and
I-outcome	2159	2166	relapse
I-outcome	2166	2167	-
I-outcome	2167	2171	free
I-outcome	2172	2180	survival
O	2180	2181	.

O	2182	2187	There
O	2188	2191	was
O	2192	2194	no
O	2195	2208	statistically
O	2209	2220	significant
O	2221	2231	difference
O	2232	2234	in
B-outcome	2235	2242	overall
I-outcome	2243	2251	survival
O	2252	2259	between
O	2260	2263	the
O	2264	2270	groups
O	2271	2272	(
O	2272	2274	HR
O	2275	2276	=
O	2277	2278	0
O	2278	2279	.
O	2279	2281	71
O	2281	2282	;
O	2283	2285	95
O	2285	2286	%
O	2287	2289	CI
O	2289	2290	,
O	2291	2292	0
O	2292	2293	.
O	2293	2295	42
O	2295	2296	-
O	2296	2297	1
O	2297	2298	.
O	2298	2300	22
O	2300	2301	,
O	2302	2303	P
O	2304	2305	=
O	2306	2307	.
O	2307	2309	22
O	2309	2310	)
O	2310	2311	.

O	2312	2314	In
O	2315	2318	the
O	2319	2330	exploratory
O	2331	2334	and
O	2335	2345	hypothesis
O	2345	2346	-
O	2346	2356	generating
O	2357	2365	subgroup
O	2366	2374	analyses
O	2375	2377	of
B-outcome	2378	2381	PCb
I-outcome	2382	2384	vs
I-outcome	2385	2388	CEF
I-outcome	2388	2389	-
I-outcome	2389	2390	T
O	2390	2391	,
O	2392	2395	the
O	2396	2398	HR
O	2399	2402	for
B-outcome	2403	2406	DFS
O	2407	2410	was
O	2411	2412	0
O	2412	2413	.
O	2413	2415	44
O	2416	2417	(
O	2417	2419	95
O	2419	2420	%
O	2421	2423	CI
O	2423	2424	,
O	2425	2426	0
O	2426	2427	.
O	2427	2429	15
O	2429	2430	-
O	2430	2431	1
O	2431	2432	.
O	2432	2434	31
O	2434	2435	;
O	2436	2437	P
O	2438	2439	=
O	2440	2441	.
O	2441	2443	14
O	2443	2444	)
O	2445	2447	in
O	2448	2456	patients
O	2457	2461	with
O	2462	2465	the
B-outcome	2466	2471	BRCA1
I-outcome	2471	2472	/
I-outcome	2472	2473	2
I-outcome	2474	2481	variant
O	2482	2485	and
O	2486	2487	0
O	2487	2488	.
O	2488	2490	39
O	2491	2492	(
O	2492	2494	95
O	2494	2495	%
O	2496	2498	CI
O	2498	2499	,
O	2500	2501	0
O	2501	2502	.
O	2502	2504	15
O	2504	2505	-
O	2505	2506	0
O	2506	2507	.
O	2507	2509	99
O	2509	2510	;
O	2511	2512	P
O	2513	2514	=
O	2515	2516	.
O	2516	2518	04
O	2518	2519	)
O	2520	2522	in
O	2523	2528	those
O	2529	2533	with
O	2534	2537	the
O	2538	2541	HRR
O	2542	2549	variant
O	2549	2550	.

O	2551	2557	Safety
O	2558	2562	data
O	2563	2567	were
O	2568	2578	consistent
O	2579	2583	with
O	2584	2587	the
O	2588	2593	known
O	2594	2600	safety
O	2601	2609	profiles
O	2610	2612	of
O	2613	2621	relevant
O	2622	2627	drugs
O	2627	2628	.

O	2629	2634	These
O	2635	2643	findings
O	2644	2651	suggest
O	2652	2656	that
O	2657	2658	a
O	2659	2669	paclitaxel
O	2669	2670	-
O	2670	2674	plus
O	2674	2675	-
O	2675	2686	carboplatin
O	2687	2694	regimen
O	2695	2697	is
O	2698	2700	an
O	2701	2710	effective
O	2711	2722	alternative
O	2723	2731	adjuvant
O	2732	2744	chemotherapy
O	2745	2751	choice
O	2752	2755	for
O	2756	2764	patients
O	2765	2769	with
O	2770	2778	operable
O	2779	2783	TNBC
O	2783	2784	.

O	2785	2787	In
O	2788	2791	the
O	2792	2795	era
O	2796	2798	of
O	2799	2808	molecular
O	2809	2823	classification
O	2823	2824	,
O	2825	2832	subsets
O	2833	2835	of
O	2836	2840	TNBC
O	2841	2850	sensitive
O	2851	2853	to
O	2854	2857	PCb
O	2858	2864	should
O	2865	2867	be
O	2868	2875	further
O	2876	2888	investigated
O	2888	2889	.

O	2890	2904	ClinicalTrials
O	2904	2905	.
O	2905	2908	gov
O	2909	2919	Identifier
O	2919	2920	:
O	2921	2932	NCT01216111
O	2932	2933	.
